The development and use of the E75 (HER2 369–377) peptide vaccine. (June 2016)

• Record Type: Journal Article
• Authors: Clifton, Guy T; Peoples, George E; Mittendorf, Elizabeth A
• Is Part Of: Future oncology. Volume 12:Number 11(2016)
• Page Start: 1321
• Page End: 1329
• Publication Date: 2016-06
• Subjects: breast cancer -- cancer vaccine -- E75 -- nelipepimut-S -- peptide; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2015-0054
• Languages: English
• ISSNs: 1479-6694

Abstract

E75 (nelipepimut-S) is an immunogenic peptide derived from the HER2 protein. When combined with the immunoadjuvant granulocyte–macrophage colony-stimulating factor (GM-CSF), nelipepimut-S has been used as a vaccine that is capable of eliciting a robust anti-HER2 immune response. Early-phase clinical trials that enrolled women with node-positive or high-risk node-negative breast cancer who had been rendered disease free with standard of care therapy but were at risk for recurrence, demonstrated the vaccine to be safe with a suggestion of clinical benefit. Nelipepimut-S is currently being evaluated in a Phase III clinical trial. This article covers the preclinical and clinical development of nelipepimut-S.